Aclaris Therapeutis (ACRS) Base Case Supported by FDA Approval of JAK Inhibitor Cream - Jefferies
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $30.00 price target on Aclaris Therapeutis (NASDAQ: ACRS) after Incyte's cream ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
